8-K current report · filed Nov 5, 2026

Zenas BioPharma, Inc. (ZBIO) 8-K Current Report: November 5, 2026

Item 2.02Item EX-99.1ZBIO overview

Short answer

Zenas BioPharma, Inc. (ZBIO) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.

Zenas BioPharma, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Full results and management commentary available in Exhibit 99.1, the accompanying press release

Item EX-99.1 · Exhibit EX-99.1

  • FDA review of obexelimab IgG4-RD BLA targets May 27, 2027, while EMA validated the MAA, advancing dual-market commercialization
  • Cash, equivalents and investments $647.1M, with projected funding through second quarter 2029 assuming $75M milestone and $75M debt draw
  • Revenue $10.0M from Bristol-Myers Squibb milestone, but net loss widened to $108.9M from $51.5M
  • R&D expense increased to $58.5M and G&A to $27.4M, reflecting expanded trials and pre-commercialization spending
  • Key catalysts remain fourth-quarter 2026 SunStone SLE results and ZB021 Phase 1 data, with orelabrutinib Phase 3 MS trials ongoing

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Zenas BioPharma, Inc. 8-K filings

Get the next ZBIO 8-K as it lands

Follow ZBIO for push alerts, or ask the research agent what this filing means.